Menu

Efficacy and Safety Data

Find out how FEIBA helped patients with hemophilia A or B inhibitors in a clinical trial.

See Data Graph showing how FEIBA can help your patients with hemophilia A and B with inhibitors

Manufacturing

FEIBA offers advanced plasma processing.

Learn More

Mechanism of Action

Multiple clotting factors of FEIBA achieved hemostasis in an in vitro analysis.2

See How It Works Mechanism of Action. Multiple clotting factors of FEIBA achieved hemostasis in an in vitro analysis
See LessMore

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in
hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is not indicated for the treatment of bleeding episodes resulting from...

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;